SG11202000941YA - Glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis - Google Patents

Glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis

Info

Publication number
SG11202000941YA
SG11202000941YA SG11202000941YA SG11202000941YA SG11202000941YA SG 11202000941Y A SG11202000941Y A SG 11202000941YA SG 11202000941Y A SG11202000941Y A SG 11202000941YA SG 11202000941Y A SG11202000941Y A SG 11202000941YA SG 11202000941Y A SG11202000941Y A SG 11202000941YA
Authority
SG
Singapore
Prior art keywords
steatohepatitis
glp
treatment
liver disease
receptor agonists
Prior art date
Application number
SG11202000941YA
Other languages
English (en)
Inventor
Aimo Kannt
Maximilian Bielohuby
Ralf Elvert
Michael Wagner
Martin Bossart
Torsten Haack
Stephanie Keil
Werner Seiz
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11202000941YA publication Critical patent/SG11202000941YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SG11202000941YA 2017-08-09 2018-08-08 Glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis SG11202000941YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306059 2017-08-09
PCT/EP2018/071478 WO2019030268A1 (en) 2017-08-09 2018-08-08 GLP-1 / GLUCAGON RECEPTOR AGONISTS FOR THE TREATMENT OF HEPATIC STEATOSIS AND STÉATOHÉPATITE

Publications (1)

Publication Number Publication Date
SG11202000941YA true SG11202000941YA (en) 2020-02-27

Family

ID=59761892

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000941YA SG11202000941YA (en) 2017-08-09 2018-08-08 Glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis

Country Status (15)

Country Link
US (1) US11352405B2 (ko)
EP (1) EP3664833B1 (ko)
JP (1) JP7230002B2 (ko)
KR (1) KR20200037358A (ko)
CN (1) CN111032071A (ko)
AU (1) AU2018314773A1 (ko)
BR (1) BR112020002503A2 (ko)
CA (1) CA3072118A1 (ko)
ES (1) ES2953631T3 (ko)
IL (1) IL272457A (ko)
MX (1) MX2020001590A (ko)
RU (1) RU2020109881A (ko)
SG (1) SG11202000941YA (ko)
TW (1) TW201920240A (ko)
WO (1) WO2019030268A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112442114A (zh) * 2019-08-29 2021-03-05 渥太华Hdl药物研发公司 一种多肽及其应用
WO2021204755A1 (en) 2020-04-06 2021-10-14 Poxel Pharmaceutical combination for the treatment of liver diseases
US11813312B2 (en) * 2020-04-24 2023-11-14 Boehringer Ingelheim International Gmbh Glucagon analogues as long-acting GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CN112472794A (zh) * 2020-11-17 2021-03-12 深圳市图微安创科技开发有限公司 双靶点激动剂多肽治疗anit介导的pbc及其相关的肝纤维化
KR20240043778A (ko) * 2021-07-30 2024-04-03 베링거 인겔하임 인터내셔날 게엠베하 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2286837A3 (en) * 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and obesity related diseases
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
UA116217C2 (uk) * 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
MA38276B1 (fr) 2012-12-21 2018-03-30 Sanofi Sa Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif.
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US10413593B2 (en) * 2014-10-24 2019-09-17 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and GLP-1 receptors
CN107614695B (zh) * 2015-04-02 2022-01-25 瑞美德生物医药科技有限公司 用胰高血糖素受体拮抗性抗体治疗肥胖症和非酒精性脂肪肝病或非酒精性脂肪性肝炎的方法
WO2016198628A1 (en) * 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CN106046145B (zh) * 2016-04-22 2022-11-04 深圳市图微安创科技开发有限公司 Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico

Also Published As

Publication number Publication date
CA3072118A1 (en) 2019-02-14
RU2020109881A3 (ko) 2021-12-15
JP2020530017A (ja) 2020-10-15
WO2019030268A1 (en) 2019-02-14
EP3664833B1 (en) 2023-05-31
IL272457A (en) 2020-03-31
CN111032071A (zh) 2020-04-17
MX2020001590A (es) 2020-03-20
AU2018314773A1 (en) 2020-03-26
JP7230002B2 (ja) 2023-02-28
ES2953631T3 (es) 2023-11-14
KR20200037358A (ko) 2020-04-08
TW201920240A (zh) 2019-06-01
BR112020002503A2 (pt) 2020-08-18
US20200216510A1 (en) 2020-07-09
EP3664833A1 (en) 2020-06-17
US11352405B2 (en) 2022-06-07
RU2020109881A (ru) 2021-09-10

Similar Documents

Publication Publication Date Title
IL272457A (en) GLP-1/Glucagon agonist receptors in the treatment of fatty liver disease and steatohepatitis
IL268702B (en) Use of a long-acting dual glp-1/glucagon receptor agonist for the treatment of non-alcoholic fatty liver disease
IL279224A (en) 1-GLP agonist receptors and their use
ZA201904616B (en) Glp-1 receptor agonists and uses thereof
HUE063074T2 (hu) GLP-1 receptor agonisták és alkalmazásuk
IL252596A0 (en) History of azabicyclooctane as fxr agonists for use in the treatment of liver and gastrointestinal diseases
IL251741A0 (en) Co-agonists for glucagon and 1- glp receptors
ZA201806637B (en) Glucagon and glp-1 co-agonists for the treatment of obesity
HK1256909A1 (zh) Glp-1和其在用於治療代謝疾病的組合物中的用途
EP3277830A4 (en) Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
ZA201702813B (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
GB201811757D0 (en) Composition comprising GLP-1 receptor agonist and glucagon receptor agonist and application thereof
IL274747A (en) FXR agonists for the treatment of liver diseases
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
IL253943A0 (en) Blockers of the growth hormone receptor in the prevention and treatment of disease
IL251024A0 (en) Antibodies against eutaxin 2 for use in the treatment of liver diseases
GB201718838D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201712742D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases